Trial Profile
FORTIS-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-Small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Talactoferrin alfa (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORTIS-M
- Sponsors Agennix AG
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 13 Aug 2012 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
- 13 Aug 2012 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov